Strains used for the preparation of bioactive peptides derived from pork ham, the bioactive peptides derived from pork ham, their preparation methods, and applications.

By controlling the fermentation process using Kluyveromyces martensii and Lactobacillus reuteri, highly efficient and safe active peptides derived from pork ham were prepared, solving the problem of insufficient mechanism in the blood sugar lowering effect of active peptides from dry-cured ham, and achieving efficient preparation of active peptides and blood sugar lowering effect.

CN116083257BActive Publication Date: 2026-11-17INST AGRO PROD PROCESSING ANHUI ACADEMY AGRI SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310092367.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-18
Publication Date
2026-11-17
Estimated Expiration
2043-01-18

AI Technical Summary

Technical Problem

The existing technology lacks sufficient research on the mechanism of blood sugar reduction of bioactive peptides derived from dry-cured ham, and the fermentation strains cannot be controlled during the preparation process, resulting in fermentation results that do not meet expectations, thus affecting the production efficiency and quality of ham-derived bioactive peptides.

Method used

Using Kluyveromyces martensii and Lactobacillus reuteri as dominant strains, pork ham-derived bioactive peptides were prepared through a process of dry curing, air drying and dehydration, aerated fermentation, stacking maturation, crude protein extraction, enzymatic hydrolysis, and separation and purification. The fermentation process was controlled to ensure the yield and quality of the bioactive peptides.

Benefits of technology

High-yield and high-quality preparation of ham-derived bioactive peptides has been achieved, exhibiting significant hypoglycemic activity, high safety, and low side effects, making them suitable for the preparation of hypoglycemic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116083257B_ABST
    Figure CN116083257B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biotechnology, specifically relating to strains for preparing porcine ham-derived bioactive peptides, porcine ham-derived hypoglycemic bioactive peptides, their preparation methods, and applications. In this invention, *Kluyveromyces martensii* and *Lactobacillus reuteri* are inoculated into the hind legs of pigs, followed by sequential processes of dry curing, air-drying dehydration, aerated fermentation, stacking maturation, crude protein extraction, enzymatic hydrolysis, and separation and purification to obtain porcine ham-derived bioactive peptides. The porcine ham-derived bioactive peptides of this invention exhibit higher hypoglycemic activity than acarbose and have a simple overall material structure. Therefore, applying these porcine ham-derived bioactive peptides to the preparation of pharmaceuticals for hypoglycemic treatment offers advantages such as high safety, low side effects, and low immunogenicity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to strains for the preparation of porcine ham-derived bioactive peptides, porcine ham-derived hypoglycemic bioactive peptides, their preparation methods, and applications. Background Technology

[0002] Diabetes has become one of the most serious and common chronic diseases, and there is still no cure. Treatment methods include oral hypoglycemic agents, insulin injections, and pancreatic islet transplantation. These treatments are costly and unaffordable for low-income groups. Furthermore, traditional drugs have their own drawbacks, which may lead to side effects or drug resistance. Insulin administration is inconvenient. There is an urgent need for new prevention, intervention, regulation, and treatment methods.

[0003] Bioactive peptides are 2-20 amino acid fragments released from proteins after hydrolysis, which can interact with certain enzymes and cell receptors in human metabolism. They have simple structures, high safety, selectivity, and potency, and low immunogenicity and hepatotoxicity / nephrotoxicity. Some bioactive peptides possess hypoglycemic activity, can intervene in early-stage hyperglycemia, thereby preventing diabetes, and have nutritional and medicinal potential. α-Amylase and α-glucosidase are two important enzymes in carbohydrate digestion; bioactive peptide sequences can regulate blood glucose levels by inhibiting the activity of these two enzymes. For example, patent CN111607628B discloses a method for preparing hypoglycemic peptides from sea cucumber and camel blood, which includes the following components in parts by weight: 1-9 parts sea cucumber polypeptide and 1-9 parts camel blood polypeptide. The above-mentioned method uses sea cucumber and camel blood as raw materials, and prepares sea cucumber hypoglycemic peptide and camel blood hypoglycemic peptide through protease hydrolysis, membrane separation and other technologies. The two are then mixed in an appropriate ratio to prepare a hypoglycemic peptide derived from sea cucumber and camel blood, which can help lower blood sugar. This preparation method is green and environmentally friendly, and realizes the high-value utilization of camel blood and sea cucumber, with broad market prospects and the potential to generate good economic and social benefits. For example, patent application CN115028697A discloses a hypoglycemic peptide and its preparation method and application. The hypoglycemic peptide is composed of the following raw materials in parts by weight: 15 parts of sea cucumber fruit meal peptide. 25 servings, broccoli seed peptides 15 25 servings, Torreya grandis kernel peptide 5 10 servings, Black Tiger Seed Peptide 5 10 servings, red ginseng fruit peptide 5 10 portions, Tiger Paw Peptide 2 4 portions, coral peptide 2 4 portions, Ganbazin peptide 2 Four samples were provided; the application of the aforementioned hypoglycemic peptides in hypoglycemic drugs was also disclosed. The aforementioned hypoglycemic peptides have high α-reactivity. Amylase inhibitory activity, meaning it possesses high hypoglycemic activity, can thus play a role in maintaining blood sugar levels in diabetic patients. However, current technologies lack research on the mechanisms by which bioactive peptides derived from cured ham lower blood sugar.

[0004] The processing of fermented meat products such as dry-cured ham is lengthy. Under the combined action of microorganisms and endogenous enzymes, muscle proteins undergo extensive hydrolysis, becoming an important source of natural bioactive peptides. Currently, ham-derived bioactive peptides are known to possess various activities, including antioxidant, blood pressure-lowering, antibacterial, blood sugar-lowering, and anti-inflammatory effects. As a natural food protein source, dry-cured ham bioactive peptides have advantages such as low molecular weight, simple structure, high safety, tolerability, selectivity, and potency, and predictable metabolic pathways. However, in the preparation of ham bioactive peptides, the raw meat undergoes natural fermentation, making it impossible to control the fermentation strains. This can lead to unsatisfactory fermentation results, interfering with the preparation and extraction of ham-derived bioactive peptides and affecting their production efficiency and quality. Summary of the Invention

[0005] To address the shortcomings of the existing technologies, this invention provides strains for preparing bioactive peptides derived from pork ham, blood sugar-lowering bioactive peptides derived from pork ham, their preparation methods, and applications. The aim is to solve the technical problems of the lack of research on the mechanisms of blood sugar lowering in bioactive peptides derived from dry-cured ham in the existing technologies, and the fact that the raw meat undergoes natural fermentation during the preparation of ham bioactive peptides, making it impossible to control the fermentation strains, resulting in unsatisfactory fermentation results, thus interfering with the preparation and extraction of ham bioactive peptides and affecting their quality.

[0006] The first technical solution provided by this invention is a strain for preparing active peptides from pork ham, and the specific technical solution is as follows: The strains used for the preparation of bioactive peptides from pork ham include *Kluyveromyces martensii* and *Lactobacillus reuteri*. *Kluyveromyces martensii* was deposited at the China Center for Type Culture Collection (CCTCC) on July 7, 2022, with accession number CCTCC NO. M20221052, and *Lactobacillus reuteri* was deposited at the same center on August 9, 2022, with accession number CCTCC NO. M20221263.

[0007] Kluyveromyces martensii belongs to the phylum Ascomycota, subphylum Saccharomycetes, order Saccharales, family Saccharidae, and genus Kluyveromyces. It possesses advantages such as high temperature tolerance, high growth rate, and the ability to utilize a wide range of carbon sources. Kluyveromyces martensii can grow and ferment at high temperatures, with some strains reaching a maximum growth temperature of 52°C. Therefore, in industrial-scale fermentation, it can reduce cooling costs and product distillation and separation costs, and can be conveniently produced in summer and tropical regions; it also significantly reduces the possibility of contamination by other microorganisms; and it can improve the catalytic efficiency of added enzymes during fermentation, thus comprehensively reducing production costs. Secondly, it has a very high growth rate, reaching 0.86–0.99 cells / h at 40°C, allowing for the rapid acquisition of large numbers of cells. Thirdly, the high salinity in the fermentation of dry-cured ham leads to high osmotic pressure, which inhibits microbial growth and fermentation. Kluyveromyces martensii cells possess the HOG1 key protein, exhibiting osmotic tolerance. Lactobacillus reuteri is a heterologous fermenting lactic acid bacterium that secretes reuterin, a non-protein substance that inhibits various pathogenic microorganisms, and synthesizes various B vitamins, including vitamin B12, and beneficial substances such as anti-inflammatory histamine. This invention replaces traditional natural fermentation with strains (Kluyveromyces martensii and Lactobacillus reuteri) used for the preparation of active peptides from pork ham, thereby achieving controllable fermentation strains in the transformation of pork into ham. This avoids interference from harmful bacteria that could produce toxic substances or result in excessively low levels of active peptides. The fermentation process is predictable, safe, and reliable, thus providing a guarantee for the subsequent preparation and extraction of active peptides from pork ham.

[0008] The second technical solution provided by this invention is a method for preparing porcine ham-derived bioactive peptides, based on the strains used for preparing porcine ham-derived bioactive peptides described in the first technical solution. The specific technical solution is as follows: The method for preparing active peptides from pork ham involves inoculating the strains used for preparing active peptides from pork ham as described in the first technical solution into the hind leg of a pig, and then sequentially performing dry curing, air drying and dehydration, aerated fermentation, stacking and maturation, crude protein extraction, enzymatic hydrolysis, separation and purification to obtain active peptides from pork ham.

[0009] Furthermore, the following steps are included: S1. Sodium chloride is added to the hind leg of the pig, and Kluyveromyces maculae and Lactobacillus reuteri are inoculated at an inoculation rate of 0.01-8% respectively for dry curing. The ham is then hung to air dry and dehydrate until the weight loss is 8-12% of the initial weight. It is then ventilated and fermented until the weight loss is 30-35% of the initial weight. After that, it is stacked and matured for 3-6 months. Fermentation is then stopped to obtain pig ham. S2, after deboning, deskinning, defatting and mincing the pork ham from step S1, add water and stir and centrifuge for the first time. Take the supernatant and centrifuge for the second time. Take the precipitate, dissolve it in water and freeze dry to obtain pork ham crude protein. S3, the crude protein of pork ham in step S2 is sequentially hydrolyzed by pepsin and trypsin and then freeze-dried to obtain crude peptides of pork ham. S4. The crude pork ham peptides from step S3 are separated and purified by affinity chromatography to obtain active pork ham peptides.

[0010] In some embodiments, in step S1, the temperature of the dry curing is 0~4℃ and the dry curing time is 7~30 days; the temperature of the ventilated fermentation is 15~30℃, the relative humidity of the ventilated fermentation is 50~80%, and the ventilated fermentation time is 3~7 days.

[0011] In some embodiments, in step S2, the ratio of the material to the liquid during stirring is 1:8 to 1:12; after the precipitate is redissolved in water, the pH is adjusted to 6.9 to 7.1 and then freeze-dried.

[0012] In some embodiments, in step S3, the pepsin treatment is specifically as follows: ham crude protein is added to a buffer solution at pH 7.0 and homogenized at 4°C. The pH is then adjusted to 1.8–2.2, and 1.5–3.5% pepsin is added. The mixture is then stirred and digested at 37°C for 2–4 hours to terminate the enzyme reaction. The trypsin treatment is specifically as follows: the pepsin-treated reactant is used as a substrate, the pH is adjusted to 7.5–8.5, and 3.0–5.0% trypsin is added. The mixture is then digested at 37°C for 1.5–3 hours to terminate the enzyme reaction.

[0013] In some embodiments, in step S4, the affinity chromatography is specifically as follows: first, dextran gel chromatography is performed, the detection wavelength of the dextran gel chromatography is 220 nm, the equilibration buffer is deionized water, and the flow rate is 1.0 ml / min; the elution method of the dextran gel chromatography is as follows: the sample concentration is 200 mg / ml, the sample volume is 1~3% of the column volume, the elution buffer is deionized water, the flow rate is 1.0 mL / min, and the detection wavelength is 220 nm; the components are then collected. The fraction collected after dextran gel chromatography was then subjected to reversed-phase silica gel chromatography. The loading concentration for reversed-phase silica gel chromatography was 40-100 mg / mL, the loading volume was 2-3% of the column volume, and the detection wavelength was 220 nm. The equilibration buffer was 20% methanol, and the flow rate was 2.0 mL / min. The elution method for reversed-phase silica gel chromatography was as follows: 0-70 min, 20% methanol; 70-130 min, 60% methanol; 130-210 min, 100% methanol. The eluent was collected and lyophilized to obtain the active peptides derived from pork ham.

[0014] The crude intracellular enzymes of *Kluyveromyces martensii* exhibit high activities of protease, aminopeptidase, and carboxypeptidase. This high activity of the intracellular enzyme system plays a crucial role in the hydrolysis of proteins and polypeptides, facilitating the production of abundant bioactive peptides from fermented ham muscle. *Lactobacillus reuteri*, belonging to the *Lactobacillus* genus, possesses a strong acid-producing capacity. The metabolic products of both *Kluyveromyces martensii* and *Lactobacillus reuteri* contain high levels of acid; lactic acid and other acids promote protein hydrolysis, breaking it down into smaller peptide molecules, thus increasing the yield of bioactive peptides. Therefore, through the above technical solutions, the preparation method of this invention is controllable, stable, and capable of producing high yields of bioactive peptides.

[0015] The third technical solution provided by this invention is a porcine ham-derived bioactive peptide, prepared using the method described in the second technical solution. The specific technical solution is as follows: Pork ham-derived bioactive peptides, wherein the pork ham-derived bioactive peptides are tripeptides to dodecapeptides with arginine or lysine at the carboxyl terminus of the peptide chain.

[0016] In some embodiments, the porcine ham-derived active peptide is one or more of PPK, PAPPK, GPR, GPQGPR, GPSGPR, AGR, GAR, IK, PPQPIK, PSR, IPSR, IIPSR, SPQPSR, GLR, GTGLR, IGR, TIGR, ITIGR, WK, DWK, DDWK, QDDWK, IR, WIR, EWIR, LEWIR, SGR, HSGR, and IHSGR.

[0017] This invention also provides a fourth technical solution: the application of porcine ham-derived active peptides. Based on the porcine ham-derived active peptides described in the third technical solution, the specific technical solution is as follows: Application of porcine ham-derived bioactive peptides: The porcine ham-derived bioactive peptides are used to prepare hypoglycemic drugs.

[0018] The porcine ham-derived bioactive peptide of this invention has an N-terminal amino acid (i.e., the first amino acid) that is either L or A, both of which are hydrophobic amino acids. More significantly, the C-terminal amino acid (i.e., the last amino acid) is either R or K, both of which are basic amino acids. The porcine ham-derived bioactive peptide of this invention exhibits higher hypoglycemic activity than acarbose, and its overall material structure is simple. Therefore, applying the porcine ham-derived bioactive peptide of this invention to the preparation of pharmaceuticals for hypoglycemic treatment has the advantages of high safety, low side effects, and low immunogenicity. Attached Figure Description

[0019] Figure 1 This is a flowchart of the preparation method of the porcine ham-derived active peptides provided by the present invention; Figure 2 These are the growth curves of *Lactobacillus reuteri* (M4-1) and *Kluyveromyces martensii* (MY4) strains in Example 1 of this invention; Figure 3 These are the acid production curves of the Lactobacillus reuteri (M4-1) and Kluyveromyces martensii (MY4) strains in Example 1 of this invention; Figure 4 This is a diagram of the crude enzyme activity of *Kluyveromyces martensii* in Example 1 of this invention; Figure 5 This is the dextran gel elution pattern of the peptide component in Example 2 of this invention; Figure 6 This is the reverse silica gel packing elution pattern of the peptide component in Example 2 of the present invention; Figure 7 This is the LC-MS / MS base peak diagram of the reverse silica filler WY-II-1 component in Example 2 of the present invention; Figure 8 This is the LC-MS / MS base peak diagram of the reverse silica filler WY-II-2 component in Example 2 of the present invention; Figure 9 This is the LC-MS / MS base peak diagram of the reverse silica filler WY-II-3 component in Example 2 of the present invention; Figure 10 This is a graph showing the results of the α-amylase inhibitory activity and α-glucosidase inhibitory activity of the three components of the reverse silica filler in Example 4 of the present invention. Detailed Implementation

[0020] To make the objectives, technical solutions, and advantages of the present invention clearer, the present invention will be further described in detail below with reference to specific embodiments and accompanying drawings.

[0021] Example 1 The strain used for preparing bioactive peptides from pork ham provided in this embodiment has the following specific technical solution: The strains used for the preparation of bioactive peptides derived from pork ham include *Kluyveromyces martensii* and *Lactobacillus reuteri*. *Kluyveromyces martensii* was deposited at the China Center for Type Culture Collection on July 7, 2022, with accession number CCTCC NO. M20221052, and *Lactobacillus reuteri* was deposited at the China Center for Type Culture Collection on August 9, 2022, with accession number CCTCC NO. M20221263.

[0022] Both *Kluyveromyces martensii* and *Lactobacillus reuteri* are edible fungi approved by the National Health and Family Planning Commission of the People's Republic of China. *Kluyveromyces martensii* belongs to the genus *Kluyveromyces* of the family Saccharomycetes, and possesses advantages such as high temperature resistance, high growth rate, and access to a wide range of carbon sources. This strain can grow and ferment at high temperatures, with some strains reaching a maximum growth temperature of 52°C. Therefore, in industrial-scale fermentation, it can reduce cooling costs and product distillation and separation costs, and can be conveniently produced in summer and tropical regions; it also significantly reduces the possibility of contamination by other microorganisms; and it can improve the catalytic efficiency of added enzymes during fermentation, thus comprehensively reducing production costs. Secondly, it has a very high growth rate, reaching 0.86–0.99 cells / h at 40°C, allowing for the rapid acquisition of large numbers of cells. Thirdly, the high salinity in the fermentation of dry-cured ham leads to high osmotic pressure, which inhibits microbial growth and fermentation. *Kluyveromyces martensii* cells possess the HOG1 key protein, exhibiting osmotic pressure tolerance. Lactobacillus reuteri is a heterologous fermenting lactic acid bacterium that can secrete reuterin, a non-protein substance that inhibits various pathogenic microorganisms, and synthesize various B vitamins, including vitamin B12, and beneficial substances such as anti-inflammatory histamine.

[0023] This embodiment focuses on the production advantages of Lactobacillus reuteri and Kluyveromyces martensii by measuring the growth curves, acid production capacity, and intracellular enzyme activity of the two strains.

[0024] 1. Growth curve determination Lactobacillus reuteri was inoculated into MRS liquid medium for activation culture (30℃, 24 h), and Kluyveromyces maculae was inoculated into YPD liquid medium for activation culture (30℃, 24 h). The culture was inoculated into the corresponding liquid medium at a 1% (v / v) inoculation rate and cultured for 48 h. Every 6 h, the bacterial culture was taken, appropriately diluted, and its OD600 value was measured to plot the bacterial growth curve.

[0025] Depend on Figure 2 It can be seen that *Lactobacillus reuteri* (M4-1) and *Kluyveromyces martensii* (MY4) enter the logarithmic growth phase after 12 hours of cultivation and enter the stationary phase after 24 hours. During the stationary phase, the cell growth (OD600) of both can reach above 2.0. This shows that both have a relatively fast growth rate and are suitable for fermentation production.

[0026] 2. Determination of acid production capacity Take the activated bacterial culture and inoculate it into the corresponding liquid culture medium at an inoculation rate of 1% (v / v) and culture for 48 h. Take the bacterial culture every 6 h, centrifuge it and determine the acid production of the strain by titration with NaOH solution.

[0027] like Figure 3As shown, after culturing *Lactobacillus reuteri* (M4-1) and *Kluyveromyces martensii* (MY4) for 24 hours, *Lactobacillus reuteri* (M4-1) produced 6-9 g / L of acid, while *Kluyveromyces martensii* (MY4) produced approximately 4 g / L of acid. Since *Lactobacillus reuteri* belongs to the *Lactobacillus* genus, it has a strong acid-producing capacity. Lactic acid and other acids are beneficial for protein hydrolysis, breaking down into smaller peptides, which can increase the yield of bioactive peptides.

[0028] 3. Determination of intracellular enzyme activity in Kluwer max yeast A solution of 5 g / 100 mL WPC and 4 g / 100 mL lactose was prepared and sterilized at 108ºC for 15 min to obtain the fermentation medium. *Kluyveromyces martensii* was activated by slant and liquid culture and then inoculated into the fermentation medium. Crude enzyme was extracted from the fermentation broth at 20 h. The fermentation broth was centrifuged at 12000 r / min for 10 min, and the supernatant was filtered through a 0.22 µm microporous membrane; the resulting liquid was the extracellular enzyme solution. 100 mL of the enzyme solution was added to ammonium sulfate to reach 20% saturation. After centrifugation to remove the precipitate, ammonium sulfate was added again to reach 60% saturation. After centrifugation, the supernatant was discarded, and the precipitate was placed in a dialysis bag and dialyzed against 10 mL of 10 mmol / L pH 6.4 PBS buffer for 60 h with magnetic stirring to obtain the purified extracellular crude enzyme solution. The extracellular crude enzyme crystals were obtained by lyophilization. Proteolytic activity was measured by digestion of azocasein. Lys-pNA and NBTpNA were used as substrates to determine the activities of aminopeptidase and carboxypeptidase, respectively.

[0029] Depend on Figure 4 The activities of protease, aminopeptidase, and carboxypeptidase in the intracellular crude enzymes isolated from the fermentation broth of *Kluyveromyces martensii* were determined. The intracellular crude enzymes of *Kluyveromyces martensii* exhibited high activities of protease, aminopeptidase, and carboxypeptidase. The high activity of the intracellular enzyme system plays an important role in the hydrolysis of proteins and peptides, which is beneficial for the fermentation of ham muscle to produce a large amount of bioactive peptides.

[0030] Example 2 The preparation method of pork ham-derived bioactive peptides provided in this embodiment is as follows: It includes the following steps: (1) Preparation of dry-cured pork ham. Select fresh pork hind legs, weighing 10-15 kg, with a pH of 5.8±0.3. After slaughter, place them at 0-4℃ and 80-90% relative humidity for 6-24 h to remove acidity. Add 6% (w / w) NaCl and inoculate with Kluyveromyces martensii (0.01-8%). Kluyveromyces marxianus*Lactobacillus reuteri*, genus *Lactobacillus*, was deposited on July 7, 2022, at the China Center for Type Culture Collection (Wuhan), accession number CCTCC NO. M20221052, and *Lactobacillus reuteri*. Lactobacillus reuteri (This species, deposited on August 9, 2022, at the China Center for Type Culture Collection (Wuhan), accession number CCTCCNO. M 20221263). The ham is dry-cured at 0–4℃ for 7–30 days, desalted with a water gun, and then hung to air-dry until the weight loss is 8–12% of the initial weight. Subsequently, it is fermented in an ventilated environment at 15–30℃ and 50–80% relative humidity for 3–7 days. When the ham has lost 30–35% of its initial weight, it is then stacked and matured for 3–6 months before fermentation is terminated. The ham is deboned, skinned, defatted, and minced. It is suspended in water at a material-to-liquid ratio of 1:8 to 1:12, and the pH is adjusted to 12.0 ± 0.1. The mixture is stirred for 1 h and centrifuged at 4500 g for 30 min at 25℃. Adjust the pH of the supernatant to 4.0±0.1, centrifuge at 4500 g for 20 min at 4℃, collect the precipitate, redissolve it in water, adjust the pH to 7.0±0.1, and freeze-dry to obtain ham crude protein, which is then stored at -18±2℃ for later use.

[0031] (2) Enzymatic hydrolysis using pepsin and trypsin. Add the crude pork ham protein from step (1) to a pH 7.0 buffer solution and homogenize at 4°C. Adjust the pH to 2.0 ± 0.2, add 1.5–3.5% pepsin, and digest at 37°C with stirring for 2–4 h. Adjust the pH to alkaline to inactivate the enzyme and terminate the reaction. Use the pepsin-digested product as a substrate, adjust the pH to 7.5–8.5, add 3.0–5.0% trypsin, and digest at 37°C for 1.5–3 h. Terminate the reaction by heating at 95°C for 5–10 min. Add anhydrous ethanol and let stand at 4°C for at least 12 h to precipitate undigested protein. Centrifuge at 10000 g for 20 min at 4°C, collect the supernatant, evaporate the ethanol in the supernatant, and freeze-dry the sample to obtain crude pork ham peptides.

[0032] (3) The crude peptides of pork ham obtained in step (2) are separated and purified (affinity chromatography) to obtain arginine or lysine peptides from pork dried cured ham protein source. The chromatography packing material includes dextran gel, detection wavelength is 220 nm, flow rate is 1.0 ml / min, equilibration buffer is deionized water, flow rate is 1.0 ml / min; the elution method of dextran gel chromatography is as follows: the sample concentration is 200 mg / ml, the sample volume is 1~3% of the column volume, the elution buffer is deionized water, the flow rate is 1.0 mL / min, the detection wavelength is 220 nm, and the fraction with the later peak and the smaller relative molecular weight is collected for subsequent separation and purification. Reversed phase silica gel chromatography, detection wavelength is 220 nm; equilibration buffer is 20% methanol. Flow rate is 2.0 ml / min. Elution method: 0-70 min, 20% methanol; 70-130 min, 60% methanol; 130-210 min, 100% methanol. The loading concentration was 40-100 mg / mL, and the loading volume was 2-3% of the column volume. The eluent was collected and freeze-dried to obtain the active peptides derived from pork ham.

[0033] Figure 5 The image shows the dextran gel elution profile of the peptide fractions. As can be seen, the peptide is mainly separated into three fractions: WY-Ⅰ (40–90 min), WY-Ⅱ (95–125 min), and WY-Ⅲ (125–160 min). According to the separation principle of molecular sieving, when peptides of different molecular weights pass through a gel chromatography column, larger peptides are eluted first, with earlier peak times, while smaller peptides are eluted later, with later peak times. Therefore, the molecular weight order of the peptide fractions after gastric and pancreatic enzyme digestion is WY-Ⅰ > WY-Ⅱ > WY-Ⅲ.

[0034] Figure 6 The image shows the elution profile of the peptide fractions using reverse-phase silica gel packing. As can be seen, elution was performed sequentially with 20%, 60%, and 100% methanol, and the separated fractions at each gradient were collected and named WY-Ⅱ-1, WY-Ⅱ-2, and WY-Ⅱ-3, respectively. According to the separation principle of ODS C18 packing, the non-polar, weakly hydrophobic fractions are eluted first, followed by the polar, strongly hydrophobic fractions. Therefore, the hydrophobicity of the three fractions is in the order WY-Ⅱ-1 < WY-Ⅱ-2 < WY-Ⅱ-3.

[0035] Figure 7-9 The figure shows the LC-MS / MS peak diagrams of the three components (WY-II-1, WY-II-2, and WY-II-3) of the reverse silica filler. As can be seen from the figure, all three components contain abundant active peptide components, while component WY-II-3 has a relatively larger variety of active peptides.

[0036] Example 3 The active peptide derived from pork ham provided in this embodiment is an active peptide prepared using the method described in Example 2. The specific technical solution is as follows: Pork ham-derived bioactive peptides, wherein the pork ham-derived bioactive peptides are tripeptides to dodecapeptides with arginine or lysine at the carboxyl terminus of the peptide chain.

[0037] Specifically, the active peptides derived from pork ham are one or more of the following: PPK, PAPPK, GPR, GPQGPR, GPSGPR, AGR, GAR, IK, PPQPIK, PSR, IPSR, IIPSR, SPQPSR, GLR, GTGLR, IGR, TIGR, ITIGR, WK, DWK, DDWK, QDDWK, IR, WIR, EWIR, LEWIR, SGR, HSGR, and IHSGR.

[0038] The hypoglycemic components and total hypoglycemic component yields of the three components (WY-II-1, WY-II-2, WY-II-3) of pork ham-derived active peptides in Example 2 were tested, and the hypoglycemic component yield of active peptides obtained by existing natural fermentation (comparative example) was tested. The results are shown in the table below.

[0039]

[0040] Example 4 This invention provides the application of porcine ham-derived bioactive peptides, with the specific technical solution as follows: Application of porcine ham-derived bioactive peptides: The porcine ham-derived bioactive peptides are used to prepare hypoglycemic drugs.

[0041] This embodiment is based on the porcine ham-derived active peptides from Example 3 (three components were finally collected after reverse silica gel packing—WY-II-1, WY-II-2, and WY-II-3, which were then freeze-dried into powder), and the in vitro hypoglycemic activities were measured as follows: Assay for α-amylase inhibitory activity: Substrate preparation: 100 mg of potato starch was boiled in 5 mL of phosphate buffer (0.1 M, pH 7.0) for 5 min and cooled to room temperature. 2 μl of sample dissolved in dimethyl sulfoxide and 50 μl of substrate were mixed in 30 μL of phosphate buffer (0.1 M, pH 7.0). The mixture was incubated at 37 °C for 5 min, then 20 μl of 5 μg / mL α-amylase solution was added, and the mixture was incubated at 37 °C for 15 min. The reaction was stopped by adding 50 μL of 1 M HCl, followed by adding 50 μL of 0.01 M iodine solution. The absorbance was measured at 650 nm. Acarbose was used as a positive control.

[0042] α-Amylase inhibition rate (%) =

[0043] Where A1 is the absorbance of the solution containing the sample, substrate, and enzyme; A2 is the absorbance of the solution containing the sample and substrate; A3 is the absorbance of the solution containing the substrate and enzyme; and A4 is the absorbance of the solution containing only the substrate.

[0044] α-Glucosidase inhibitory activity assay: 50 μl of pH 6.8, 0.2 M sodium phosphate buffer, 50 μl of 1 mg / mL PNPG, and 50 μl of sample were added to a 96-well microplate. The mixture was then thoroughly mixed and incubated at 37°C for 5 min. Subsequently, 10 μl of 0.2 U / mL α-glucosidase solution prepared in buffer was added, and the reaction started immediately. The plate was incubated at 37°C for another 30 min. Finally, 80 μl of 1 M Na₂CO₃ solution was added to terminate the reaction, and the absorbance of the product PNP was immediately measured at 405 nm. A 10 mg / mL acarbose solution prepared in buffer was used as a positive control. The percentage of α-glucosidase inhibition was calculated as follows: α-glucosidase inhibition rate (%) =

[0045] Among them, OD A It is the absorbance of the sample after it has been replaced with an equal volume of buffer solution; OD S It is the absorbance of the sample after the enzyme reaction; OD B It is the absorbance after both the sample and α-glucosidase have been replaced with an equal amount of buffer.

[0046] The results are as follows Figure 10 (In the figure: the positive control is acarbose; the sample concentration for α-amylase inhibitory activity is 5 mg / ml; the sample concentration for α-glucosidase inhibitory activity is 10 mg / ml; different capital letters indicate significant differences in α-amylase inhibitory activity; different capital letters indicate significant differences in α-glucosidase inhibitory activity) As shown, the porcine ham-derived active peptides prepared in Example 2 have high inhibition rates against both α-amylase and α-glucosidase, and exhibit good hypoglycemic activity.

[0047] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. The present invention is not limited to the examples described above. Any changes, modifications, additions, or substitutions made by those skilled in the art within the scope of the present invention should also fall within the protection scope of the present invention.

Claims

1. A compound bacterial strain for the preparation of bioactive peptides derived from pork ham, characterized in that, The contents include *Kluyveromyces martensii* and *Lactobacillus reuteri*. *Kluyveromyces martensii* was deposited at the China Center for Type Culture Collection (CCTCC) on July 7, 2022, with accession number CCTCC NO. M20221052, and *Lactobacillus reuteri* was deposited at the same center on August 9, 2022, with accession number CCTCC NO. M20221263.

2. A method for preparing porcine ham-derived bioactive peptides, based on the compound strain for preparing porcine ham-derived bioactive peptides as described in claim 1, characterized in that, The compound strain for preparing active peptides from pork ham as described in claim 1 was inoculated into the hind leg of a pig, and then subjected to dry curing, air drying and dehydration, aeration fermentation, stacking and maturation, crude protein extraction, enzymatic hydrolysis, separation and purification to obtain active peptides from pork ham.

3. The method for preparing porcine ham-derived bioactive peptides according to claim 2, characterized in that, Includes the following steps: S1. Sodium chloride is added to the hind leg of the pig, and Kluyveromyces maculae and Lactobacillus reuteri are inoculated at an inoculation rate of 0.01-8% respectively for dry curing. The ham is then hung to air dry and dehydrate until the weight loss is 8-12% of the initial weight. It is then ventilated and fermented until the weight loss is 30-35% of the initial weight. After that, it is stacked and matured for 3-6 months. Fermentation is then stopped to obtain pig ham. S2, after deboning, deskinning, defatting and mincing the pork ham from step S1, add water and stir and centrifuge for the first time. Take the supernatant and centrifuge for the second time. Take the precipitate, dissolve it in water and freeze dry to obtain pork ham crude protein. S3, the crude protein of pork ham in step S2 is sequentially hydrolyzed by pepsin and trypsin and then freeze-dried to obtain crude peptides of pork ham. S4. The crude pork ham peptides from step S3 are separated and purified by affinity chromatography to obtain active pork ham peptides.

4. The method for preparing porcine ham-derived bioactive peptides according to claim 3, characterized in that, In step S1, the temperature for dry curing is 0~4℃ and the curing time is 7~30 days; the temperature for ventilated fermentation is 15~30℃, the relative humidity for ventilated fermentation is 50~80%, and the fermentation time is 3~7 days.

5. The method for preparing the porcine ham-derived bioactive peptide according to claim 3, characterized in that, In step S2, the ratio of the material to the liquid during stirring is 1:8 to 1:12; after the precipitate is redissolved in water, the pH value is adjusted to 6.9 to 7.1 and then freeze-dried.

6. The method for preparing the porcine ham-derived bioactive peptide according to claim 3, characterized in that, In step S3, the pepsin treatment is specifically as follows: Ham crude protein is added to a pH 7.0 buffer solution and homogenized at 4°C. The pH is then adjusted to 1.8–2.2, and 1.5–3.5% pepsin is added. The mixture is then stirred and digested at 37°C for 2–4 hours to terminate the enzyme reaction. The trypsin treatment is specifically as follows: The pepsin-treated reactant is used as a substrate, the pH is adjusted to 7.5–8.5, and 3.0–5.0% trypsin is added. The mixture is then digested at 37°C for 1.5–3 hours to terminate the enzyme reaction.

7. The method for preparing porcine ham-derived bioactive peptides according to claim 3, characterized in that, In step S4, the affinity chromatography is specifically as follows: first, dextran gel chromatography is performed, with a detection wavelength of 220 nm, deionized water as the equilibration buffer, and a flow rate of 1.0 ml / min; the elution method for the dextran gel chromatography is as follows: the sample concentration is 200 mg / ml, the sample volume is 1-3% of the column volume, the elution buffer is deionized water, the flow rate is 1.0 mL / min, the detection wavelength is 220 nm, and the components are collected; The fraction collected after dextran gel chromatography was then subjected to reversed-phase silica gel chromatography. The loading concentration for reversed-phase silica gel chromatography was 40-100 mg / mL, the loading volume was 2-3% of the column volume, and the detection wavelength was 220 nm. The equilibration buffer was 20% methanol, and the flow rate was 2.0 mL / min. The elution method for reversed-phase silica gel chromatography was as follows: 0-70 min, 20% methanol; 70-130 min, 60% methanol; 130-210 min, 100% methanol. The eluent was collected and lyophilized to obtain the active peptides derived from pork ham.

Citation Information

Patent Citations

  • A blood sugar-lowering peptide from sea cucumber and camel blood

    CN111607628B

  • Hypoglycemic peptide as well as preparation method and application thereof

    CN115028697A

  • Almond small molecule peptide for inhibiting activity of alpha-glucosidase and application of almond small molecule peptide

    CN115466305A